Efficacy and Safety of Cinobufacin Combined with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis.

Efficacy and Safety of Cinobufacin Combined with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2020;2020:4953539 Authors: Xu J, Li D, Du K, Wang J Abstract Background: Cinobufacin is a Chinese patent medicine widely used for breast cancer in China. However, no systematic review and meta-analysis have been published to validate its effects in breast cancer treatment. We, therefore, summarize the efficacy and safety of Cinobufacin combined with chemotherapy in order to provide rigid evidence for its clinical application. Methods: By searching multiple databases incepted to December 2019, the RCTs of breast cancer patients treated with Cinobufacin were screened according to the inclusion criteria, and the meta-analysis and sensitivity analysis were conducted using RevMan5.3. Results: A total of 1163 articles were retrieved, and 16 studies were included. The total sample size was 1331 cases, including 666 cases in the treatment group receiving Cinobufacin combined with chemotherapy and 665 cases in the control group receiving chemotherapy alone. Our study found that the ORR (overall response rate) (RR = 1.35, 95% CI: [1.23, 1.49], P
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research

Related Links:

IJERPH, Vol. 17, Pages 7160: Understanding the Public’s Emotions about Cancer: Analysis of Social Media Data International Journal of Environmental Research and Public Health doi: 10.3390/ijerph17197160 Authors: Seul Ki Park Hyeoun-Ae Park Jooyun Lee Cancer survivors suffer from emotional distress, which varies depending on several factors. However, existing emotion management programs are insufficient and do not take into consideration all of the factors. Social media provides a platform for understanding the emotions of the public. The aim of this study was to explore the relationship between the public...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Conclusions The anti-Notch3 ADC PF-06650808 has demonstrated a manageable safety profile and early signs of antitumor activity in patients with advanced BC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
Despite the wide pharmacological armamentarium available for the treatment of metastatic breast cancer (MBC), long-lasting control of disease is challenging, especially in heavily pretreated patients. In this case report, we documented a long-lasting complete response (CR) with eribulin in a relatively young woman with MBC and bone metastasis, who did not benefit from prior chemotherapy regimens. Besides CR, the patient was able to maintain an excellent performance status and was free from the severe pain experienced before the initiation of eribulin. Noteworthy, eribulin treatment was very well tolerated, with only a mild...
Source: Oncology - Category: Cancer & Oncology Source Type: research
Abstract Despite the wide pharmacological armamentarium available for the treatment of metastatic breast cancer (MBC), long-lasting control of disease is challenging, especially in heavily pretreated patients. In this case report, we documented a long-lasting complete response (CR) with eribulin in a relatively young woman with MBC and bone metastasis, who did not benefit from prior chemotherapy regimens. Besides CR, the patient was able to maintain an excellent performance status and was free from the severe pain experienced before the initiation of eribulin. Noteworthy, eribulin treatment was very well tolerated...
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
This study assesses whether a scalp-cooling device is effective in reducing chemotherapy-induced alopecia, and assesses adverse treatment effects. MATERIALS AND METHODS: A prospective observational study including women with breast cancer undergoing chemotherapy and scalp cooling using a Paxman device. The primary efficacy end points were: successful hair preservation (no hair loss;
Source: Breast - Category: Cancer & Oncology Authors: Tags: Breast Source Type: research
This article summarizes FDA decision-making and data supporting the approval of ribociclib. PMID: 29437768 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
You get one ailment, and it always seems to bring along its'friends'. A few examples are cancer with chemotherapy causes digestive issuesand temporary baldness. It can sometimes also cause long term cardiac issues - which can eventually kill you. With rheumatoid arthritis you can get things like Sjogren's Syndrome which causes dry eyes and other fun things. Afew examples are:" ... [RA]inflammation can result in conditions affecting skin, heart, lung, eyes, mental health, etc. Conditions likeosteoporosis, cataracts,depression, cancers, etc. are more common. And add to that infection based conditions like influenza, pne...
Source: Caroline's Breast Cancer Blog - Category: Cancer & Oncology Tags: ailments being a patient comorbidities Source Type: blogs
ConclusionsFurther qualitative research is needed to understand how patients distinguish cancer-related symptoms from treatment-related side effects, to gain insight into which patient experiences should be measured and how best to measure them.
Source: The Patient - Patient-Centered Outcomes Research - Category: Global & Universal Source Type: research
Abstract PURPOSE: Health Related Quality of life (HRQoL) is increasingly recognised as an important indicator of outcome and well-being in oncology care. We set out in this study to evaluate whether significant association exists between anxiety disorders (ADs) and HRQoL in breast cancer, such that any intervention addressing ADs would potentially improve HRQoL. METHODS: A cross sectional evaluation of 200 attendees of an oncology clinic was done using designed questionnaire to gather socio-demographic and clinical data. Subsequently, the Schedule for clinical Assessment in Neuropsychiatry was used to ascerta...
Source: Breast - Category: Cancer & Oncology Authors: Tags: Breast Source Type: research
More News: Alopecia | Alternative and Complementary Therapies | Brain | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | China Health | Complementary Medicine | Databases & Libraries | Gastroenterology | Liver | Neurology | Pain | Statistics | Study | Urology & Nephrology